Spots Global Cancer Trial Database for ak104
Every month we try and update this database with for ak104 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | NCT05377658 | Non-small Cell ... | AK104 Albumin-Bound P... Carboplatin | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | NCT05559541 | Solid Tumor, Ad... | AK119 AK104 | 18 Years - | Akeso | |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma | NCT04728321 | Hepatocellular ... | AK104 lenvatini... AK104 | 18 Years - 75 Years | Akeso | |
| A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma | NCT05008783 | Gastric Adenoca... Gastroesophagea... | AK104 Placebo | 18 Years - 75 Years | Akeso | |
| A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | NCT05215067 | Advanced Non-sm... | AK104 Docetaxel | 18 Years - 75 Years | Akeso | |
| AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer | NCT06062589 | Cervical Cancer | Iodine-125 part... AK104 | 18 Years - 70 Years | Peking University Third Hospital | |
| A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | NCT04444141 | Peripheral T-ce... | AK104 | 18 Years - 75 Years | Akeso | |
| AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC | NCT05522894 | Unresectable Es... Locally Advance... Metastatic Esop... | AK104 Cisplatin Paclitaxel | 18 Years - 75 Years | ChineseAMS | |
| Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | NCT05853172 | Gastric Cancer | AK104 Apatinib Paclitaxel S-1 | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC | NCT05319431 | Unresectable, N... | AK104 Lenvatinib TACE | 18 Years - 75 Years | Akeso | |
| Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer | NCT05980689 | Locally Advance... | AK104 Capecitabine Neoadjuvant Rad... | 18 Years - 75 Years | Sun Yat-sen University | |
| AK104 in Neoadjuvant Treatment of Cervical Cancer | NCT05227651 | Cervical Cancer | AK104 | 18 Years - 75 Years | Akeso | |
| A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors | NCT05235542 | Advanced Malign... | AK104 AK117 Capecitabine ta... Oxaliplatin Cisplatin Paclitaxel Irinotecan Docetaxel 5-FU | 18 Years - 75 Years | Akeso | |
| A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | NCT05489289 | Hepatocellular ... | AK104 placebo | 18 Years - 75 Years | Akeso | |
| A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | NCT05215067 | Advanced Non-sm... | AK104 Docetaxel | 18 Years - 75 Years | Akeso | |
| A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | NCT05808608 | Renal Cell Carc... First-line Trea... Non Clear Cell ... Sarcomatoid Ren... | AK104 Axitinib | 18 Years - 75 Years | West China Hospital | |
| AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | NCT05904379 | Advanced Non-sm... | AK112 AK104 Carboplatin paclitaxel pemetrexed Docetaxel | 18 Years - 75 Years | Akeso | |
| Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | NCT05559541 | Solid Tumor, Ad... | AK119 AK104 | 18 Years - | Akeso | |
| Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） | NCT05794750 | Locally Advance... | AK104 injection TME surgery Capecitabine Oxaliplatin | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma | NCT06371157 | Hepatocellular ... | AK104 Lenvatinib TACE Placebo for AK1... Placebo for Len... | 18 Years - 75 Years | Akeso | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital | |
| A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | NCT05489289 | Hepatocellular ... | AK104 placebo | 18 Years - 75 Years | Akeso | |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | NCT04444167 | Hepatocellular ... | AK104 Lenvatinib | 18 Years - 75 Years | Akeso | |
| A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer | NCT06251388 | Cervical Cancer | AK104 | 18 Years - 75 Years | West China Second University Hospital | |
| A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | NCT06178601 | Urothelial Carc... | RC48-ADC AK104 | 18 Years - | Shanxi Province Cancer Hospital | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours | NCT05021120 | Advanced or Met... | AK127 AK104 | 18 Years - | Akeso | |
| AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer | NCT06062589 | Cervical Cancer | Iodine-125 part... AK104 | 18 Years - 70 Years | Peking University Third Hospital | |
| A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | NCT05990127 | Locally Advance... | AK104 Tislelizumab carboplatin Pemetrexed Paclitaxel | 18 Years - | Akeso | |
| A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | NCT06178601 | Urothelial Carc... | RC48-ADC AK104 | 18 Years - | Shanxi Province Cancer Hospital | |
| Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery | NCT06209294 | Neoadjuvant Imm... Cervical Cancer Fertility-spari... | AK104 Carboplatin Nab paclitaxel | 18 Years - 45 Years | Fudan University | |
| Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） | NCT05794750 | Locally Advance... | AK104 injection TME surgery Capecitabine Oxaliplatin | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma | NCT05256472 | Renal Cell Carc... First-line Trea... | AK104 axitinib | 18 Years - 75 Years | Akeso | |
| A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | NCT04982237 | Cervical Cancer | AK104 paclitaxel carboplatin cisplatin bevacizumab Placebo | 18 Years - 75 Years | Akeso | |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | NCT06424626 | Melanoma Mucosal Melanom... Metastatic Mela... | AK104+Axitinib AK112+Axitinib | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | NCT04380805 | Recurrent Cervi... Metastatic Cerv... | AK104 | 18 Years - | Akeso | |
| Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | NCT05853172 | Gastric Cancer | AK104 Apatinib Paclitaxel S-1 | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix | NCT05063916 | Carcinomas Cervix Cancer Cervical Cancer | AK104 | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | NCT04444167 | Hepatocellular ... | AK104 Lenvatinib | 18 Years - 75 Years | Akeso | |
| Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix | NCT05063916 | Carcinomas Cervix Cancer Cervical Cancer | AK104 | 18 Years - | M.D. Anderson Cancer Center | |
| Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer | NCT05980689 | Locally Advance... | AK104 Capecitabine Neoadjuvant Rad... | 18 Years - 75 Years | Sun Yat-sen University | |
| AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | NCT05377658 | Non-small Cell ... | AK104 Albumin-Bound P... Carboplatin | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | NCT05215067 | Advanced Non-sm... | AK104 Docetaxel | 18 Years - 75 Years | Akeso | |
| A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | NCT06074484 | Muscle Invasive... | RC48-ADC AK104 | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) | NCT05896787 | Esophageal Squa... | AK104, nab-pacl... | 18 Years - 70 Years | The First Affiliated Hospital of Zhengzhou University | |
| Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery | NCT06209294 | Neoadjuvant Imm... Cervical Cancer Fertility-spari... | AK104 Carboplatin Nab paclitaxel | 18 Years - 45 Years | Fudan University | |
| A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | NCT04982237 | Cervical Cancer | AK104 paclitaxel carboplatin cisplatin bevacizumab Placebo | 18 Years - 75 Years | Akeso | |
| A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | NCT04444141 | Peripheral T-ce... | AK104 | 18 Years - 75 Years | Akeso | |
| A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | NCT05990127 | Locally Advance... | AK104 Tislelizumab carboplatin Pemetrexed Paclitaxel | 18 Years - | Akeso | |
| A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer | NCT04868708 | Recurrent or Me... | AK104 Bevacizumab Paclitaxel Cisplatin or Ca... | 18 Years - 75 Years | Akeso | |
| Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) | NCT05896787 | Esophageal Squa... | AK104, nab-pacl... | 18 Years - 70 Years | The First Affiliated Hospital of Zhengzhou University | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
